Skip to main
ANIK

Anika Therapeutics (ANIK) Stock Forecast & Price Target

Anika Therapeutics (ANIK) Analyst Ratings

Based on 1 analyst ratings
Buy
Strong Buy 0%
Buy 100%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Anika Therapeutics Inc. has demonstrated a robust financial performance, with international osteoarthritis (OA) pain revenue increasing by 21% compared to the previous year, supported by favorable order timing. The company’s regenerative solutions segment experienced a notable 25% growth, largely attributed to the Integrity patch, which has newly received 510K clearances for various applications, enhancing its market potential. Furthermore, Anika's strong fourth quarter exceeded expectations, featuring a free cash flow of $5 million, significantly outperforming prior estimates and indicating a strong trajectory for revenue growth as the company plans to increase procedures and revenue substantially by 2025.

Bears say

Anika Therapeutics reported a revenue decline of 5.9% year-over-year, generating $27.8 million, falling short of revenue and adjusted EBITDA expectations while achieving only modest success in cash generation. The company faces ongoing challenges with gross margins, reporting 56% due to production yield issues, and anticipates a significant revenue decline of 16-20% in its OEM channel, primarily driven by price pressures in the U.S. Additionally, the failure of its pivotal FastTrack trial for Hyalofast raises concerns about future product efficacy and market competitiveness, further contributing to a negative outlook for the company's financial performance.

Anika Therapeutics (ANIK) has been analyzed by 1 analysts, with a consensus rating of Buy. 0% of analysts recommend a Strong Buy, 100% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Anika Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Anika Therapeutics (ANIK) Forecast

Analysts have given Anika Therapeutics (ANIK) a Buy based on their latest research and market trends.

According to 1 analysts, Anika Therapeutics (ANIK) has a Buy consensus rating as of Apr 18, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $17, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $17, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Anika Therapeutics (ANIK)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.